Publications by authors named "A Yuile"
Multilayer ceramic capacitors (MLCCs) are critical components when thermal processes such as reflow desoldering are used during rework of electronic assemblies. The capacitor's ferroelectric BaTiO body is very brittle. Therefore, thermomechanical stresses can cause crack formation and create conductive paths that may short the capacitor.
View Article and Find Full Text PDFAims: Therapeutic drug monitoring (TDM) has led to significant improvements in individualized medical care, although its implementation in oncology has been limited to date. Tyrosine kinase inhibitors (TKIs) are a group of therapies for which TDM has been suggested. Osimertinib is one such therapy used in the treatment of epidermal growth factor receptor (EGFR) mutation-driven lung cancer.
View Article and Find Full Text PDFArticle Synopsis
- Osimertinib, a drug for non-small cell lung cancer (NSCLC), can cause toxicity, leading to the need for dose adjustments; this study aimed to measure osimertinib and its active metabolites in dried blood spots (DBS) using a specialized hemaPEN device and compare results to plasma measurements.
- A validated method using ultrahigh-performance liquid chromatography-tandem mass spectrometry was developed to accurately quantify osimertinib and its metabolites from both plasma and DBS, demonstrating no significant bias linked to hematocrit levels in patient samples.
- The study concluded that measuring these drugs in DBS is a reliable and easier alternative for therapeutic drug monitoring, showing similar results to those obtained
Article Synopsis
- Platinum-based chemotherapy combined with anti-PD-1 or PD-L1 monoclonal antibodies is now the standard first-line treatment for advanced non-small cell lung cancer (mNSCLC) without specific mutations.
- A network meta-analysis was conducted using data from 24 randomized control trials to compare the effectiveness of anti-PD-1 and anti-PD-L1 therapies, focusing on overall survival (OS) and other key outcomes.
- Results indicated that anti-PD-1 plus chemotherapy offers better overall survival, progression-free survival, and response rates compared to anti-PD-L1 plus chemotherapy, especially in patients with certain PD-L1 expression levels, highlighting the need for future direct comparisons between these treatments.
Article Synopsis
- Genomic alterations in astrocytomas have been studied for decades, particularly the impact of homozygous deletions (HD) of specific genes, which are now critical criteria for diagnosing WHO grade 4 astrocytomas.
- The genes in question are located on chromosome 9 and play a role in regulating cell growth; however, understanding how various alterations like heterozygous deletions and point mutations affect prognosis remains complex.
- The literature review highlights the challenges in interpreting the prognostic value of these alterations as glioma classification evolves, emphasizing the need for standardized research methods to enhance clinical decision-making.